Extract
Treating allergic bronchopulmonary aspergillosis (ABPA) remains a challenge for clinicians, as little high-quality data exists on the optimal treatment regimen. ABPA is widely accepted to correspond to an exaggerated immune response toA. fumigatus口服皮质类固醇是第一道治疗[1,2]。口服类固醇通常与吸入的皮质类固醇(ICS)有关,这在哮喘患者的治疗中是强制性的。已经提出了抗真菌唑作为对哮喘患者的ABPA的辅助治疗,已有二十多年[3]。在类固醇依赖性患者中,通常建议伊曲康唑作为一种附加疗法[2],在患有ABPA的患者和/或对口服类固醇反应不足的患者中,与ICS相结合[1]。目前缺少这种方法的确定证据,因为先前的研究是在少数患者和短时间内进行的研究[3,4]。
抽象的
The effect of adding itraconazole to prednisolone shown in an open-labelled study has no firmly established mechanism and could be related to greater exposure to steroids. The risk of selecting azole-resistantA. fumigatus应考虑菌株。https://bit.ly/30nl3zr
脚注
利益冲突:A。Havette无话可说。
Conflict of interest: L. Regard has nothing to disclose.
利益冲突:N。Roche宣布向Boehringer Ingelheim,Novelheim,Novartis,Glaxosmithkline和Pfizer宣布赠款(支付给机构);Boehringer Ingelheim,Glaxosmithkline,Astrazeneca,Sanofi,Chiesi,Chiesi,Pfizer,Novartis和Teva获得的咨询费;以及Boehringer Ingelheim,Glaxosmithkline,Astrazeneca,Sanofi,Chiesi,Chiesi,Pfizer,Novartis,Teva和Zambon的付款或酬金。
Conflict of interest: P-R. Burgel declares grants (paid to institution) from Boehringer Ingelheim, Vertex and GlaxoSmithKline; consulting fees from Vertex, GlaxoSmithKline, AstraZeneca and Chiesi; and payment or honoraria from Boehringer Ingelheim, GlaxoSmithKline, AstraZeneca, Vertex, Chiesi, Pfizer, Novartis, Insmed and Zambon, all in the 36 months prior to manuscript submission.
- 已收到2021年11月12日。
- Accepted2021年11月17日。
- 版权所有©作者2022。用于复制权和权限联系permissions{at}ersnet.org